Watch more videos about polycythemia vera. Visit the MPNConnect YouTube channel at [ Ссылка ]

Raajit K. Rampal, MD, PhD, Assistant Attending Physician, Leukemia Service at Memorial Sloan Kettering, discusses the importance of assessing the risk of a thrombotic event as part of designing polycythemia vera treatment plans.

Learn more about polycythemia vera. Visit [ Ссылка ]

Brought to you by Incyte Corporation.

How can tailoring therapy in polycythemia vera (PV) help manage the risk of thrombosis?

[…] the optimal timing of therapy really depends on what we mean by therapy. Now that really relates to a patient’s risk of thrombosis. We know that patients who are over the age of sixty, and who have ever had a thrombotic event, are at the highest risk of having a subsequent thrombotic event. For those patients, they usually require a cytoreductive type of therapy, and that can be in the form of hydroxyurea, or interferon, or other modalities. In patients who are lower risk for thrombosis, those are patients less than age sixty or who’ve never had a thrombotic event, those patients usually will require phlebotomy and aspirin as the mainstays of therapy. Regardless of the risk score, all patients will require some form of therapy at the outset when they are diagnosed.

© 2016 Incyte Corporation. All rights reserved. EDU-1360d 02/16

свернуть